HER2, a transmembrane receptor tyrosine kinase in the epidermal growth factor receptor family, is amplified or overexpressed in approximately 20% of breast cancers and is associated with poor prognosis, although good response to HER2-targeted therapies [4,6]. Here, ERBB2 is linked to breast carcinoma.